The Most Common Myths and Misunderstandings About the GLP-1 Drug List
Most myths about this drug list start with treating it as a ranked menu of interchangeable products. It is not. It is a short set of molecules sold under paired brand names, each approved for a narrow use, sitting next to a far larger market of unapproved copies and investigational agents nobody can be prescribed.
Myth: they are all essentially the same drug
They share a receptor and diverge from there. Semaglutide, liraglutide, dulaglutide, and exenatide activate the GLP-1 receptor. Tirzepatide activates the GLP-1 receptor and the GIP receptor together, which places it in a different pharmacological category despite the shared shorthand. Dosing rhythm varies too, from twice daily for exenatide to daily for liraglutide to weekly for the rest.
Duration of action, receptor selectivity, and the size of effect observed in trials all differ. Grouping them under one heading is a convenience of language, not a statement about equivalence.
| Drug | Sold as | Mechanism | What the FDA label approves it for |
|---|---|---|---|
| Tirzepatide | Zepbound | Activates GIP and GLP-1 receptors | Reducing and maintaining reduced body weight, and treating moderate to severe obstructive sleep apnea in adults with obesity |
| Tirzepatide | Mounjaro | Activates GIP and GLP-1 receptors | Improving glycemic control in type 2 diabetes from age 10 upward |
| Semaglutide | Wegovy | Activates the GLP-1 receptor | Reducing and maintaining reduced body weight, lowering cardiovascular event risk in established heart disease, and treating MASH with moderate to advanced fibrosis |
| Semaglutide | Ozempic | Activates the GLP-1 receptor | Improving glycemic control in type 2 diabetes, with cardiovascular and kidney outcome uses |
| Liraglutide | Saxenda and Victoza | Activates the GLP-1 receptor, dosed daily | Saxenda for body weight reduction, Victoza for glycemic control in type 2 diabetes |
| Dulaglutide | Trulicity | Activates the GLP-1 receptor | Glycemic control in type 2 diabetes and cardiovascular event risk reduction |
Myth: Ozempic is the weight loss drug
Ozempic is approved for type 2 diabetes. Its label covers blood glucose control, cardiovascular event reduction in patients with established cardiovascular disease, and slowing kidney decline in chronic kidney disease. The semaglutide product approved for weight is Wegovy, with a different dose ceiling and a different pen.
The confusion is understandable given the same molecule sits in both. It stops being harmless when someone assumes a diabetes prescription will be covered for weight, or that the two versions are dispensed interchangeably.
Myth: compounded semaglutide is the generic version
There is no approved generic of semaglutide or tirzepatide in the United States. Compounded preparations are made by pharmacies under a separate part of federal drug law, not through the abbreviated pathway that produces generic medicines. They carry no FDA finding of safety, efficacy, or manufacturing quality, and FDA has published warnings specifically about unapproved GLP-1 products sold for weight loss.
A disproportionality study of adverse event reports filed between 2018 and 2024 found compounded GLP-1 products carried higher reporting odds for preparation errors, contamination, prescribing errors, and hospitalization than approved formulations. That design shows a signal, not a cause, and the report volume for compounded products was small against the total. It is still the opposite of what “generic” implies to most people.
What separates one compounded route from another is oversight rather than chemistry. Ro, Hims and Hers, and a long tail of smaller telehealth services source from different registered pharmacies under different arrangements, and the quality of a preparation depends on that sourcing chain and on the provider behind it rather than on the molecule printed on the vial. Anyone comparing cash options is really comparing pharmacies and prescriber oversight.
Myth: tirzepatide beat semaglutide in a head-to-head trial of the weight products
The most quoted comparison, roughly 15 percent against roughly 21 percent, comes from two separate trials with different populations, durations, and placebo responses. Lining those figures up gives a direction, not a margin.
Real comparative evidence does exist and should be described for what it is. A propensity-matched cohort study using electronic health records from more than 18,000 matched adults found greater on-treatment weight reduction with tirzepatide than with semaglutide, using formulations labeled for type 2 diabetes, with similar rates of gastrointestinal adverse events. That is observational data from clinical practice rather than a randomized comparison of the weight-labeled products. A separate published subpopulation analysis from a randomized tirzepatide versus semaglutide program reported the same direction in a defined subgroup.
The direction has held up across evidence types. The precise size of the gap, for any individual, has not been established by any of it.
Myth: the newest agents are available if you look hard enough
Retatrutide, survodutide, and CagriSema are investigational compounds. None of those holds FDA approval, though orforglipron, once grouped with them, has since been approved as an oral product. For the investigational three, so none can be dispensed on a prescription. Products sold online under those names are not the studied agents, and no timeline for any of them can be inferred from trial publications or company statements.
Myth: a long list means plenty of choice
Count the molecules rather than the brand names and the list collapses to five with current United States labels. Filter for products approved for weight management and three remain. Add formulary placement, prior authorization criteria, and local stock, and most patients face a decision between two options, sometimes one.
Older entries have thinned the list further. Exenatide extended-release and lixisenatide no longer return active listings in the federal label database, so the historical class roster overstates what is currently on pharmacy shelves.
Myth: you stop once the target is reached
Obesity guidelines treat these agents as long-term therapy for a chronic condition. Withdrawal studies consistently show regain, and maintenance trials show that continued dosing preserves reductions that placebo does not. Framing a course as temporary sets up the outcome most people are trying to avoid, and it changes the financial calculation entirely, since a treatment measured in years is judged on sustainable monthly cost rather than on an initial price.
That long-term framing also reshapes how the cash market should be read. Because the cost that matters is the one repeated every month for years, providers such as Henry Meds, LifeMD, and HealthRX are better compared on their standing monthly rate for GLP-1 medications than on a first-visit promotion. A course priced to be sustainable is worth more than one priced to look cheap at signup and then quietly dropped.
Frequently asked questions
Does a bigger average weight loss make a drug better for everyone?
No. Trial averages describe groups, and individual responses in those cohorts ranged from far above the mean to almost nothing. Tolerance, existing conditions, dosing rhythm, and whether a person can keep paying for the drug all shape the outcome more than the headline percentage does.
Are compounded versions cheaper because they skip marketing costs?
They are cheaper mainly because they skip the approval process, the trial program, and the manufacturing standards attached to an approved product. Marketing spend is a small part of the difference. The regulatory status is the substantive part of it.
Is the GIP receptor activity in tirzepatide proven to be what drives the difference?
Not conclusively. The dual mechanism is well documented and the effect sizes in trials are larger, but reviews of incretin pharmacology still describe the exact contribution of GIP signaling to weight outcomes as an area of active investigation rather than settled science.
Can a drug on this list be used for prediabetes?
None of these products carries a prediabetes indication. Some are prescribed to people with prediabetes who meet the weight criteria on a weight management label, which is a different justification, and one that insurers assess separately from any glucose reading.